Target Corporation (TGT)
Target Stock Tumbles 15% in 3 Months: Buy the Dip or Stay Cautious?
TGT's margins and sales remain pressured, yet digital growth, AI upgrades and new merchandising strategies offer hope for improvement.
Target Corporation Still Lacks Growth Drivers, But Valuation Has Already Priced In Too Many Risks
Target Corporation is upgraded to a cautious buy as valuation becomes increasingly attractive despite ongoing headwinds and muted growth prospects. TGT trades at historically low multiples, with downside risks likely priced in, and offers a compelling 5.12% dividend yield supported by sustainable payouts. Recent quarters show stabilizing sales declines and robust fundamentals, including strong cash flow, prudent debt management, and improving product category trends.
Target (TGT) Laps the Stock Market: Here's Why
In the closing of the recent trading day, Target (TGT) stood at $90.38, denoting a +1.24% move from the preceding trading day.
Is Curtiss-Wright Stock Still A Buy After A 40% Rally? I Share My Updated Price Target
Curtiss-Wright Corporation continues to benefit from strong aerospace, defense, and nuclear energy market tailwinds, driving robust sales and margin growth. CW raised its full-year 2025 guidance, now expecting 9-10% sales growth, 15-18% operating income growth, and improved free cash flow outlook. Despite a significant rally and fair 2026 valuation, CW offers 13% upside when considering 2027 earnings, supported by strong EBITDA and cash flow growth.
Bitcoin: Uptober Arrived, And My New Target Price Too!
Reiterate a buy rating on Bitcoin, citing renewed perspectives with new ETFs. The on-chain metrics studied also seem like a great combination to take Bitcoin to a new ATH. Despite modest September gains, BTC is decoupling from traditional assets, offering portfolio diversification and risk management benefits. Maintain a $138,000 target price for BTC by the end of 2025, supported by strong seasonality and expanding institutional participation, while noting risks from large holder sell-offs.
Target Corporation (TGT) is Attracting Investor Attention: Here is What You Should Know
Target (TGT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
3 Dirt Cheap Stocks to Buy With $1,000 Right Now
The S&P 500 index (^GSPC 0.59%) is hovering near all-time highs. And yet shares of retailer Target (TGT 1.02%) have lost 66% of their value.
The Travelers Companies: Expecting Another Strong Quarter, Raising My Price Target
The Travelers Companies remains a "Buy," with shares undervalued and technicals signaling a potential breakout ahead of Q3 earnings. TRV delivered strong Q2 results, including a significant EPS beat, improved combined ratio, and robust shareholder returns via dividends and buybacks. Sell-side sentiment is positive for TRV, with 21 EPS upgrades in the past 90 days and no downgrades, supporting an optimistic earnings outlook.
TGT Faces Earnings Pressure as Tariffs and Lower Spend Bite Margins
Target posts mixed results in the fiscal second quarter as tariffs and cautious shoppers cut into margins, even as store traffic and digital demand improved.
Where Will Target Stock Be in 5 Years?
Target (TGT 0.55%) continues to struggle to win over investors. Business and political challenges have weighed on the stock.
AMC Networks Could Become The Next Takeover Target In Streaming Media Content
AMC Networks offers deep value, trading at a steep discount to cash holdings and sector peers, with strong free cash flow and manageable debt until 2029. AMCX's $866 million cash cushion and $250 million in annual FCF supports liquidity, reducing near-term risks. Short sellers may be off the mark. The stock is a potential takeover target in my opinion, with low enterprise valuations and robust gross profit margins making it the most attractive asset in the entertainment sector.
The New Olink Target 48 Neurodegeneration Panel May Boost TMO Stock
Thermo Fisher unveils the Olink Target 48 Neurodegeneration panel to accelerate biomarker research in neurodegenerative diseases.
